Solangepras

Solangepras
Clinical data
Other names	Solengepras; CVN-424; CVN424
Routes of; administration	Oral
Drug class	GPR6 inverse agonist
Identifiers
	IUPAC name 1-[2-[4-(2,4-difluorophenoxy)piperidin-1-yl]-3-[[(3R)-oxolan-3-yl]amino]-7,8-dihydro-5H-pyrido[3,4-b]pyrazin-6-yl]ethanone;
CAS Number	2254706-21-1;
PubChem CID	137359492;
DrugBank	DB18958;
ChemSpider	114869317;
UNII	XO01711URG;
KEGG	D12980;
ChEMBL	ChEMBL4778540;
Chemical and physical data
Formula	C24H29F2N5O3
Molar mass	473.525 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)N1CCC2=C(C1)N=C(C(=N2)N3CCC(CC3)OC4=C(C=C(C=C4)F)F)N[C@@H]5CCOC5;
	InChI InChI=1S/C24H29F2N5O3/c1-15(32)31-10-6-20-21(13-31)28-23(27-17-7-11-33-14-17)24(29-20)30-8-4-18(5-9-30)34-22-3-2-16(25)12-19(22)26/h2-3,12,17-18H,4-11,13-14H2,1H3,(H,27,28)/t17-/m1/s1; Key:HSWVJQBEXRKOBZ-QGZVFWFLSA-N;

Solangepras (INNTooltip International Nonproprietary Name; developmental code name CVN-424), or solengepras (USANTooltip United States Adopted Name), is an inverse agonist of the orphan G protein-coupled receptor 6 (GPR6) which is under development for the treatment of Parkinson's disease.^[1]^[2]^[3]^[4] It is a small molecule and is taken by mouth.^[1]^[4] Solangepras produces hyperlocomotion and reverses haloperidol-induced catalepsy in rodents.^[4] It is being developed by Cerevance.^[1]^[2] As of October 2024, solangepras is in phase 3 clinical trials.^[1]^[2]

References

^ ^a ^b ^c ^d ^e "Solengepras". AdisInsight. 21 October 2024. Retrieved 25 February 2025.
^ ^a ^b ^c "Delving into the Latest Updates on CVN-424 with Synapse". Synapse. 5 February 2025. Retrieved 25 February 2025.
^ Gros P, Garcia LA, Fox SH (2025). "Experimental Therapeutics in Parkinson's Disease". Neurologic Clinics. doi:10.1016/j.ncl.2024.12.013.
^ ^a ^b ^c Brice NL, Schiffer HH, Monenschein H, Mulligan VJ, Page K, Powell J, et al. (June 2021). "Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease". The Journal of Pharmacology and Experimental Therapeutics. 377 (3): 407–416. doi:10.1124/jpet.120.000438. PMID 33795395.